DYAX

Why You Should Believe (and Buy) the Current Rebound in Biotech Stocks

By Hilary Kramer, Editor, GameChangers
Price gouging may have summoned Hillary Clinton's wrath, but the selloff in biotech stocks was built on fearmongering, while the rebound is being built on actual substance.

Stocks Surge to Start November

By Anthony Mirhaydari, InvestorPlace Market Strategist
Investors look ahead to the remainder of the Q3 earnings season, a number of Fed speakers on Wednesday and the all-important October jobs report on Friday.

Biotech News: Shire (SHPG) to Buy Dyax (DYAX) in $5.9B Deal

By William White, InvestorPlace Writer
Drugmaker Shire has announced that it plans to purchase Dyax for $5.9 billion with a possible $646 million bonus for a drug approval.

Why Barrick Gold Corporation (USA) (ABX), Nabors Industries Ltd. (NBR) and Dyax Corp. (DYAX) are 3 of Today’s Best Stocks

By Ethan Roberts, InvestorPlace Contributor
A dismal ADP report couldn't prevent Barrick Gold (ABX), Nabors Industries (NBR) and Dyax (DYAX) from having a great Wednesday.

Dyax (DYAX) Stock: Meteoric Rally After Blowout Clinical Trial

By John Divine, InvestorPlace Assistant Editor
Dyax (DYAX) stock is up more than 50% in Tuesday trading after its preventive HAE treatment, DX-2930, performed well in clinical trials.